在患有遗传胆固醇疾病的患者中, 新阿姆斯特丹药业的药物obicetrapib显著降低坏胆固醇. NewAmsterdam Pharma's drug obicetrapib significantly reduces bad cholesterol in patients with a genetic cholesterol condition.

在NewAmsterdam Pharma的第三期试验中,在患有不控制的异构糖家族高胆固醇血清症的患者中,奥比塞特拉皮布在84天后有效降低了LDL- C的36. 3%,在365天后降低了41. 5%. NewAmsterdam Pharma's Phase 3 trial showed that obicetrapib effectively reduced LDL-C by 36.3% at 84 days and 41.5% at 365 days in patients with uncontrolled heterozygous familial hypercholesterolemia. 该药物还大大降低了Lp(a)水平,得到很好的容忍,血压没有增加。 The drug also significantly lowered Lp(a) and was well tolerated with no increase in blood pressure. NewAmsterdam希望今年晚些时候从正在进行的研究中获得更多的数据。 NewAmsterdam expects more data from ongoing studies later this year.

文章

Market Screener

GlobeNewswire

WallStreet Online

-- 显示更少 --

延伸阅读

相关故事